Assembly Biosciences Q2 2024: Cash Down, Arbutus Deal Details
Ticker: ASMB · Form: 10-Q · Filed: 2024-08-08T00:00:00.000Z
Sentiment: neutral
Topics: financials, cash-burn, partnership
TL;DR
Assembly Bio's cash dropped to $200.6M in Q2, down from $230.7M end of '23. Arbutus deal details in filing.
AI Summary
Assembly Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $200.6 million as of June 30, 2024, a decrease from $230.7 million at the end of 2023. The filing also references an agreement with Arbutus Biopharma, with details related to the period of April 1, 2024, to June 30, 2024.
Why It Matters
This filing provides insight into Assembly Biosciences' financial health and ongoing strategic partnerships, crucial for investors assessing the company's operational runway and future prospects.
Risk Assessment
Risk Level: medium — The company's cash position has decreased, and the nature of biopharmaceutical development carries inherent risks.
Key Numbers
- $200.6M — Cash and Cash Equivalents (As of June 30, 2024, indicating a decrease from the prior year-end.)
- $230.7M — Cash and Cash Equivalents (As of December 31, 2023, providing a comparison point for the current period.)
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Filer
- $200.6 million (dollar_amount) — Cash and cash equivalents as of June 30, 2024
- $230.7 million (dollar_amount) — Cash and cash equivalents as of December 31, 2023
- Arbutus Biopharma (company) — Partner in an agreement
- June 30, 2024 (date) — End of reporting period
- December 31, 2023 (date) — Prior year-end reporting date
FAQ
What was Assembly Biosciences' cash and cash equivalents balance at the end of Q2 2024?
As of June 30, 2024, Assembly Biosciences, Inc. reported cash and cash equivalents of $200.6 million.
How does the Q2 2024 cash balance compare to the end of 2023?
The cash and cash equivalents balance of $200.6 million as of June 30, 2024, is a decrease from $230.7 million reported as of December 31, 2023.
What is the reporting period for this 10-Q filing?
This 10-Q filing covers the period ending June 30, 2024.
Is there any mention of specific agreements or partnerships in the filing?
Yes, the filing references an agreement with Arbutus Biopharma, with details pertaining to the period of April 1, 2024, to June 30, 2024.
What was the company's former name?
The company's former name was Ventrus Biosciences Inc., with a date of name change on February 11, 2008.
From the Filing
0000950170-24-093998.txt : 20240808 0000950170-24-093998.hdr.sgml : 20240808 20240808161524 ACCESSION NUMBER: 0000950170-24-093998 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 241188556 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 10-Q 1 asmb-20240630.htm 10-Q 10-Q 0001426800 Q2 --12-31 false .1429 .0588 .0833 .0833 .0833 http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember 0001426800 us-gaap:CommonStockMember asmb:SecuritiesPurchaseAgreementMember 2024-06-01 2024-06-30 0001426800 us-gaap:RetainedEarningsMember 2022-12-31 0001426800 srt:MaximumMember 2023-09-30 0001426800 asmb:ArbutusBiopharmaAgreementMember 2024-04-01 2024-06-30 0001426800 us-gaap:FairValueInputsLevel1Member asmb:USAndForeignCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001426800 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001426800 srt:MinimumMember 2024-04-01 2024-06-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001426800 srt:MinimumMember 2023-01-01 2023-06-30 0001426800 2023-04-01 2023-06-30 0001426800 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001426800 us-gaap:FairValueInputsLevel3Member asmb:USAndForeignCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001426800 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001426800 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001426800 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001426800 us-gaap:FairValueInputsLevel2Member asmb:USAndForeignCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:CommonStockMember 2024-03-31 0001426800 us-gaap:MoneyMarketFundsMember 2023-12-31 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember 2023-04-01 2023-06-30 0001426800 us-gaap:WarrantMember asmb:GileadSciencesIncorporatedMember srt:MaximumMember us-gaap:PrivatePlacementMember asmb:SecuritiesPurchaseAgreementMember 2024-06-01 2024-06-30 0001426800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001426800 asmb:OptionLicenseAndCollaborationAgreementMember asmb:GileadSciencesIncorporatedMember 2024-01-01 2024-06-30 0001426800 us-gaap:CommonStockMember 2023-